The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation. Authorized by Congress in the FDA Reauthorization Act of 2017, the designation provides certain incentives for industry to develop generics for drugs lacking competition. FDA Commissioner Scott Gottlieb, M.D., said the agency also will advance additional policies over the next year to promote generic competition. “This will include the publication of a series of guidances to address regulatory and scientific challenges that make it generally more difficult to develop complex generics,” he said. “As part of this, we intend to issue draft guidance with recommendations on establishing active ingredient sameness. In addition, we’ll advance the development of new analytical tools and in vitro tests to provide additional accurate, sensitive and reproducible tools to support approval of complex generic drugs.”

Related News Articles

Headline
Health and Human Services Secretary Alex Azar today released a plan outlining two pathways the administration intends to explore to safely import certain drugs…
Headline
The Senate Finance Committee today voted 19-9 to pass the Prescription Drug Pricing Reduction Act, legislation to reduce drug costs.
Headline
Senate Finance Committee Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore., today released a description of the chairman’s mark, the…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…
Headline
A federal judge yesterday struck down a Centers for Medicare…